2-Methoxyestradiol inhibits prostate tumor development in transgenic adenocarcinoma of mouse prostate: Role of tumor necrosis factor-α- stimulated gene 6

Clinical Cancer Research

Volumn 12, Issue 3 I, 2006, Pages 980-988

  Garcia, Gretchen E ^f   Wisniewski, Hans Georg ^b   Lucia, M Scott ^c   Arevalo, Nicole ^g   Slaga, Thomas J ^a   Kraft, Susan L ^d   Strange, Robert ^e   Kumar, Addanki P ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d Department of Environmental and Radiological Health Sciences   (United States)

^e AMC Cancer Research Center   (United States)

^f NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^g Affinity BioReagents   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; TUMOR NECROSIS FACTOR ALPHA;

ADENOCARCINOMA; ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CANCER INVASION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN EXPRESSION; TUMOR GROWTH;

ADENOCARCINOMA; ANIMALS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; DIET; DISEASE MODELS, ANIMAL; ESTRADIOL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS;

EID: 32944476631     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2068     Document Type: Article

References (48)

1. Pienta KJ, Smith DC. Advances in prostate cancer therapy: a new era begins. CA Cancer J Clin 2005;55:300-18.
2. Sakr WA, Grignon DJ, Crissman JD, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study. In vivo 1994;8:439-43.
3. Shen CA, Shen MM. Molecular genetics of prostate cancer. Genes Dev 2001;14:2410-34.
4. Tricolli JV, Schoenfeldt M, Conley BA. Detection of prostate cancer and predicting progression: current and future diagnostic markers. Clin Cancer Res 2004;10:3943-53.
5. Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower. J Am Med Assoc 2005;294:66-70.
6. 2/M phase and inhibits growth of human prostate cancer cells. Mol Carcinog 2001;31:111-24.
7. 2-terminal kinase-mediated pathways in 2-methoxyestradiol- induced p53 induction and apoptosis. Carcinogenesis 2003;24:1067-75.
8. Gingrich JR, Barrios RJ, Foster BA, Greenberg NM. Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis 1999;2:70-5.
9. Gupta S, Ahmad N, Marengo SR, MacLennan GT, Greenberg NM, Mukhtar H. Chemoprevention of prostate carcinogenesis by α-difluoromethylornithine in TRAMP mice. Cancer Res 2000;60:5125-33.
10. Mentor-Marcel R, Lamartiniere CA, Eltoum IE, Greenberg NM, Elgavish A. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res 2001;61:6777-82.
11. Kasper S, Smith JA, Jr. Genetically modified mice and their use in developing therapeutic strategies for prostate cancer. J Urol 2004;172:12-9.
12. Wisniewski H-G, Maier R, Lotz M, et al. TSG-6: a TNF-, IL-1-, and LPS-inducible secreted glycoprotein associated with arthritis. J Immunol 1993;151:6593-601.
13. Wisniewski HG, Vilcek J. Cytokine-induced gene expression at the crossroads of innate immunity, inflammation and fertility: TSG-6 and PTX3/TSG-14. Cytokine Growth Factor Rev 2004;15:129-46.
14. Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci U S A 2001;98:10350-5.
15. Kumar AP, Garcia GE, Ghosh R, Ranjnarayanan RV, Alworth WL, Slaga TJ. 4-Hydroxy3-methoxybenzoic acid methyl ester: a curcumin derivative targets Akt/NFκB cell survival signaling pathway: potential for prostate cancer management. Neoplasia 2003;5:255-66.
16. Westfall P, Young SS. Resampling based multiple testing. New York: John Wiley & Sons; 1996.
17. Zeng Yu, Yokohira M, Saoo K, et al. Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by raloxifene, an antiestrogens with anti-androgen action, but not nimesulide, a selective cyclooxygenase inhibitor. Carcinogenesis 2005;26:1109-16.
18. Zhu BT, Conney AH. Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res 1998;58:2269-77.
19. Seegers JC, Lottering ML, Grobler CJ, et al. The mammalian metabolite 2-methoxyestradiol alters p53 levels and apoptosis induction in transformed cells. J Steroid Biochem Mol Biol 1997;62:253-67.
20. Davoodpour P, Landstorm M. 2-Methoxyestradiol induced apoptosis in prostate cancer cells requires Smad 7. J Biol Chem 2005;280:14773-9.
21. Gao N, Rahmani M, Dent P, Grant S. 2-Methoxyestradiol-induced apoptosis in human leukemia cells proceeds through a reactive oxygen species and Akt-dependent process. Oncogene 2005;24:3797-809.
22. Ho Shuk-Mei. Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. J Cell Biochem 2004;91:491-503.
23. Blundell CD, Almond A, Mahoney DJ, DeAngelis PL, Campbell ID, Day AJ. Towards a structure for a TSG-6.hyaluronan complex by modeling and NMR spectroscopy: insights into other members of the link module superfamily. J Biol Chem 2005;280:18189-201.
24. Kahmann JD, O'Brien R, Werner JM, et al. Localization and characterization of the hyaluronan-binding site on the link module from human TSG-6. Structure Fold Des 2000;8:763-74.
25. Kohda D, Morton CJ, Parkar AA, et al. Solution structure of the link module: a hyaluronan-binding domain involved in extracellular matrix stability and cell migration. Cell 1996;86:767-75.
26. Mahoney DJ, Blundell CD, Day AJ. Mapping the hyaluronan-binding site on the link module from human tumor necrosis factor-stimulated gene-6 by site-directed mutagenesis. J Biol Chem 2001;276:22764-71.
27. Wisniewski HG, Snitkin ES, Mindrescu C, Sweet MH, Vilcek J. TSG-6 protein binding to glycosaminoglycans: formation of stable complexes with hyaluronan and binding to chondroitin sulfates. J Biol Chem 2005;280:14476-84.
28. Wisniewski H-G, Hua J-C, Poppers DM, Naime D, Vilcek J, Cronstein BN. TNF/IL-1-inducible protein TSG-6 potentiates plasmin inhibition by inter-α-inhibitor and exerts a strong anti-inflammatory effect in vivo. J Immunol 1996;156:1609-15.
29. Getting SJ, Mahoney DJ, Cao T, et al. The link module from human TSG-6 inhibits neutrophil migration in a hyaluronan- and inter-α-inhibitor- independent manner. J Biol Chem 2002;277:51068-76.
30. Bardos T, Kamath RV, Mikecz K, Glant TT. Anti-inflammatory and chondroprotective effect of TSG-6 (tumor necrosis factor-α-stimulated gene-6) in murine models of experimental arthritis. Am J Pathol 2001;159:1711-21.
31. Giant TT, Kamath RV, Bardos T, et al. Cartilage-specific constitutive expression of TSG-6 protein (product of tumor necrosis factor α-stimulated gene 6) provides a chondroprotective, but not antiinflammatory, effect in antigen-induced arthritis. Arthritis Rheum 2002;46:2207-18.
32. Mindrescu C, Thorbecke GJ, Klein MJ, Vilcek J, Wisniewski H-G. Amelioration of collagen-induced arthritis in DBA/1J mice by recombinant TSG-6, a tumor necrosis factor/interleukin-1-inducible protein. Arthritis Rheum 2000;43:2668-77.
33. Mindrescu C, Dias AAM, Olszewski RJ, Klein MJ, Reis LFL, Wisniewski H-G. Amelioration of collagen-induced arthritis in DBA/1J mice by recombinant TSG-6, a tumor necrosis factor/interleukin-1-inducible protein. Arthritis Rheum 2002;46:2453-64.
34. Wisniewski HG, Vilcek J. TSG-6: an IL-1/TNF-inducible protein with anti-inflammatory activity. Cytokine Growth Factor Rev 1997;8:143-56.
35. Jacobs EJ, Rodriguez C, Mondul AM, et al. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst 2005;97:975-80.
36. Palapattu G, Sutcliffe S, Bastian PJ, et al. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 2005;26:1170-81.
37. Zhang M, Altuwaijri S, Yeh S. RRR-α-tocopheryl succinate inhibits human prostate cancer cell invasiveness. Oncogene 2004;23:3080-9.
38. Sweeney C, Liu G, Yiannoutsos C, et al. A phase II multicenter, randomized double bind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin Cancer Res 2005;11:6625-33.
39. Klampfer L, Lee TH, Hsu W, Vilcek J, Chen-Kiang S. NF-IL6 and AP-1 cooperatively modulate the activation of the TSG-6 gene by tumor necrosis factor α and interleukin-1. Mol Cell Biol 1994;14:6561-9.
40. Klampfer L, Chen-Kiang S, Vilcek J. Activation of the TSG-6 gene by NF-IL6 requires two adjacent NF-IL6 binding sites. J Biol Chem 1995;70:3677-82.
41. Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 2001;11:372-7.
42. 1 arrest of human fibroblasts after γ-irradiation or N-phosphoacetyl-L-aspartate treatment. Carcinogenesis 2000;21:2203-10.
43. Kuznetsova SA, Day AJ, Mahoney DJ, Rugg MS, Mosher DF, Roberts DD. The N-terminal module of thrombospondin-1 interacts with the link domain of TSG-6 and enhances its covalent association with the heavy chains of inter-α-trypsin inhibitor. J Biol Chem 2005;280:30899-908.
44. Lawler J, Detmar M. Tumor progression: the effects of thrombospondin-1 and -2. Int J Biochem Cell Biol 2004;36:1038-45.
45. Gutierrez LS, Suckow M, Lawler J, Ploplis VA, Castellino FJ. Thrombospondin 1-a regulator of adenoma growth and carcinoma progression in the APC(Min/+) mouse model. Carcinogenesis 2003;24:199-207.
46. Lipponen P, Aaltomaa S, Tammi R, Tammi M, Agren U, Kosma VM. High stromal hyaluronan level is associated with poor differentiation and metastasis in prostate cancer. Eur J Cancer 2001;37:849-56.
47. Bowen C, Bubendorf L, Voeller JH, et al. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res 2000;60:6111-5.
48. Ruiz M, Troncoso P, Bruns C, Bar - Eli M. Activator protein 2α transcription factor expression is associated with luminal differentiation and is lost in prostate cancer. Clin Cancer Res 2001;7:4086-95.